The current classification of acute myeloid leukemia (AML) relies largely on genomic
alterations. AML with mutated nucleophosmin 1 (NPM1-mut) is the largest of the genetically …

Understanding the underlying mechanism of acute myeloid leukemia (AML) has led to the
discovery of novel biomarkers to help predict, treat and monitor leukemia. DNA (cytosine-5) …

Abstract Background Nucleophosmin 1 (NPM1) gene‐mutated acute myeloid leukemia
(NPM1 mut AML) is classified as a subtype with a favorable prognosis. However, some …

Acute myeloid leukemia (AML) is a complex and heterogeneous disease characterized by
different genetic or cytogenetic abnormalities. Additionally, epigenetic alterations are …

Acute myeloid leukemia (AML) patients with DNA methyltransferase 3A (DNMT3A) mutation
display poor prognosis, and targeted therapy is not available currently. Our previous study …

Mutations in the nucleophosmin 1 (NPM1 mut) gene are the commonest molecular lesions
occurring in≥ 50% of cases with acute myeloid leukemia (AML) without cytogenetic …

Background The high clinical and molecular heterogeneity of acute myeloid leukemia (AML)
has led to an unsatisfactory clinical prognosis, thus we sought to incorporate both clinical …

We discuss the clinical characteristics and prognostic significance of adult individuals with
PTPN11 mutations who have developed acute myeloid leukemia (AML)(none acute …

Введение. Одно из проявлений пролиферации опухолевых клеток при остром
миелоидном лейкозе (ОМЛ)–лейкоцитоз. В работе мы оцениваем ассоциацию …

Background The human gene DNMT3A (DNA methyltransferase 3 alpha) is involved in DNA
de novo methylation essential for genome regulation and development. Pathogenic variants …